Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database
Abstract
Objective Recent advances in giant cell arteritis (GCA) management aim to reduce glucocorticoid (GC). We described changes in treatment patterns over time in real life and assessed associations between cumulative GC use and adverse outcomes. Methods This retrospective population-based study used the French national health insurance database (Système National des Données de Santé) and included 18 301 incident GCA cases between 2010 and 2022. Latent class growth modelling identified GC use trajectories. We described trends in cumulative dose and sparing agent use. Multivariable survival models assessed factors associated with sustained GC-free remission and association between GC cumulative exposure and mortality, serious infections, major adverse cardiovascular events (MACE) and osteoporotic fractures. Results Four GC use trajectories were identified. Two high-dose trajectories declined over time. Yet, mean 2-year cumulative GC dose remained high, reaching 7.6 g among patients diagnosed in 2022. Methotrexate use increased until 2020 and plateaued thereafter while tocilizumab prescriptions rose, reaching over 25% in 2022. Male sex and baseline methotrexate or tocilizumab use were associated with faster GC tapering, while age >75 years, hypertension, kidney and neurodegenerative diseases were associated with slower tapering. Each gram of GC was associated with higher mortality (HR per gram 1.024, 95% CI 1.021 to 1.027). Yearly cumulative exposure to doses ≤5 mg/day was associated with increased infection (HR 1.13, 95% CI 1.00 to 1.29) and MACE (HR 1.04, 95% CI 1.01 to 1.08). Conclusion Despite reductions in high-dose use, cumulative GC exposure in GCA remains substantial and associated with adverse outcomes, even at the lowest doses.
Related
- Frequencies of thyroid-related diagnoses and dyslipidemia among Japanese women with menstrual-related disorders aged under 40 years: A nationwide cross-sectional study using health insurance claims data
- Individual variation in glucocorticoid plasticity to temperature is not associated with reproductive success in a wild songbird population
- Untargeted serum metabolomics in systemic lupus erythematosus reveals candidate metabolomic signatures associated with clinical phenotypes and glucocorticoid use
- Opioid agonist treatment and risk of mortality in French primary care: a nationwide, retrospective cohort study
- Phenotypic characterization of patients with ANCA-associated vasculitis and diffuse alveolar hemorrhage: a data-driven analysis of a multicentre, retrospective, nationwide cohort
BibTeX
@article{beydon2026glucocorticoid,
title = {{Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database}},
author = {Maxime Beydon and Diane Lacaille and Bruno Fautrel and Raphaèle Seror and David Hajage and Florence Tubach},
journal = {RMD Open},
year = {2026},
month = jul,
doi = {10.1136/rmdopen-2026-006866},
url = {https://hal.science/hal-05784268v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Glucocorticoid in giant cell arteritis: real-world treatment patterns over time and associated burden in a nationwide hospital-based study within the French health insurance database
AU - Maxime Beydon
AU - Diane Lacaille
AU - Bruno Fautrel
AU - Raphaèle Seror
AU - David Hajage
AU - Florence Tubach
PY - 2026
DA - 2026/07/07
JO - RMD Open
DO - 10.1136/rmdopen-2026-006866
UR - https://hal.science/hal-05784268v1
AB - Objective Recent advances in giant cell arteritis (GCA) management aim to reduce glucocorticoid (GC). We described changes in treatment patterns over time in real life and assessed associations between cumulative GC use and adverse outcomes. Methods This retrospective population-based study used the French national health insurance database (Système National des Données de Santé) and included 18 301 incident GCA cases between 2010 and 2022. Latent class growth modelling identified GC use trajectories. We described trends in cumulative dose and sparing agent use. Multivariable survival models assessed factors associated with sustained GC-free remission and association between GC cumulative exposure and mortality, serious infections, major adverse cardiovascular events (MACE) and osteoporotic fractures. Results Four GC use trajectories were identified. Two high-dose trajectories declined over time. Yet, mean 2-year cumulative GC dose remained high, reaching 7.6 g among patients diagnosed in 2022. Methotrexate use increased until 2020 and plateaued thereafter while tocilizumab prescriptions rose, reaching over 25% in 2022. Male sex and baseline methotrexate or tocilizumab use were associated with faster GC tapering, while age >75 years, hypertension, kidney and neurodegenerative diseases were associated with slower tapering. Each gram of GC was associated with higher mortality (HR per gram 1.024, 95% CI 1.021 to 1.027). Yearly cumulative exposure to doses ≤5 mg/day was associated with increased infection (HR 1.13, 95% CI 1.00 to 1.29) and MACE (HR 1.04, 95% CI 1.01 to 1.08). Conclusion Despite reductions in high-dose use, cumulative GC exposure in GCA remains substantial and associated with adverse outcomes, even at the lowest doses.
SN - 2056-5933
ER -